^ abcCohen JD, Van Putten T, Marder S, Berger PA, Stahl SM (October 1987). “The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia”. Journal of Clinical Psychopharmacology7 (5): 324–9. doi:10.1097/00004714-198710000-00006. PMID2890671.
^Olson GL, Cheung HC, Morgan KD, et al. (September 1981). “A dopamine receptor model and its application in the design of a new class of rigid pyrrolo[2,3-g]isoquinoline antipsychotics”. Journal of Medicinal Chemistry24 (9): 1026–34. doi:10.1021/jm00141a002. PMID6116805.
^ abDavidson AB, Boff E, MacNeil DA, Wenger J, Cook L (1983). “Pharmacological effects of Ro 22-1319: a new antipsychotic agent”. Psychopharmacology79 (1): 32–9. doi:10.1007/BF00433013. PMID6132425.
^Collin S, Vercauteren DP, Vanderveken D, Evrard G, Durant F (March 1989). “Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands”. Journal of Computer-aided Molecular Design3 (1): 39–53. doi:10.1007/BF01590994. PMID2715795.
^Uhr SB, Berger PA, Pruitt B, Stahl SM (October 1984). “Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist”. The New England Journal of Medicine311 (15): 989. doi:10.1056/NEJM198410113111517. PMID6147753.
^Uhr SB, Pruitt B, Berger PA, Stahl SM (April 1986). “Case report of four patients with Tourette syndrome treated with piquindone, a D2 receptor antagonist”. Journal of Clinical Psychopharmacology6 (2): 128–30. doi:10.1097/00004714-198604000-00028. PMID2871057.
^Uhr SB, Pruitt B, Berger PA, Stahl SM (July 1986). “Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist”. International Clinical Psychopharmacology1 (3): 216–20. doi:10.1097/00004850-198607000-00004. PMID3549873.